Cargando…

Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid

The goal of this study is to investigate the pharmacokinetics in plasma and tumour interstitial fluid of two T-cell bispecifics (TCBs) with different binding affinities to the tumour target and to assess the subsequent cytokine release in a tumour-bearing humanised mouse model. Pharmacokinetics (PK)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eigenmann, Miro Julian, Karlsen, Tine Veronica, Wagner, Marek, Tenstad, Olav, Weinzierl, Tina, Fauti, Tanja, Grimm, Hans Peter, Skogstrand, Trude, Klein, Christian, Sam, Johannes, Umana, Pablo, Bacac, Marina, Wiig, Helge, Walz, Antje-Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705663/ https://www.ncbi.nlm.nih.gov/pubmed/34959386 http://dx.doi.org/10.3390/pharmaceutics13122105

Ejemplares similares

A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis
por: Van De Vyver, Arthur, et al.
Publicado: (2021)

Na(+) is shifted from the extracellular to the intracellular compartment and is not inactivated by glycosaminoglycans during high salt conditions in rats
por: Thowsen, Irene Matre, et al.
Publicado: (2022)

Interstitial fluid: the overlooked component of the tumor microenvironment?
por: Wiig, Helge, et al.
Publicado: (2010)

Effect of Topical Anaesthetics on Interstitial Colloid Osmotic Pressure in Human Subcutaneous Tissue Sampled by Wick Technique
por: Guthe, Hans Jørgen Timm, et al.
Publicado: (2012)

Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood
por: Haslene-Hox, Hanne, et al.
Publicado: (2014)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2020)

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2021)

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
por: Bacac, Marina, et al.
Publicado: (2016)

A New Method for Isolation of Interstitial Fluid from Human Solid Tumors Applied to Proteomic Analysis of Ovarian Carcinoma Tissue
por: Haslene-Hox, Hanne, et al.
Publicado: (2011)

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
por: Aspelund, Aleksanteri, et al.
Publicado: (2015)

VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats
por: Samuelsson, Anne-Maj, et al.
Publicado: (2023)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

PKPD modeling of acquired resistance to anti-cancer drug treatment
por: Eigenmann, Miro J., et al.
Publicado: (2017)

Proteomic analysis of formalin-fixed paraffin-embedded glomeruli suggests depletion of glomerular filtration barrier proteins in two-kidney, one-clip hypertensive rats
por: Finne, Kenneth, et al.
Publicado: (2014)

0729. Interstitial changes in spleen during sepsis
por: Svendsen, ØS, et al.
Publicado: (2014)

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
por: Schanzer, Juergen M., et al.
Publicado: (2016)

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
por: Kerns, S Jordan, et al.
Publicado: (2021)

Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications
por: Wagner, Marek, et al.
Publicado: (2015)

Abnormal neonatal sodium handling in skin precedes hypertension in the SAME rat
por: Mullins, Linda, et al.
Publicado: (2021)

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model
por: Cremasco, Floriana, et al.
Publicado: (2021)

Interstitial Fluid Colloid Osmotic Pressure in Healthy Children
por: Guthe, Hans Jørgen Timm, et al.
Publicado: (2015)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

The notochord in Atlantic salmon (Salmo salar L.) undergoes profound morphological and mechanical changes during development
por: Kryvi, Harald, et al.
Publicado: (2017)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance
por: Liu, Can, et al.
Publicado: (2023)

Impaired lymphatic function accelerates cancer growth
por: Steinskog, Eli Sihn Samdal, et al.
Publicado: (2016)

The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice
por: Reigstad, Inga, et al.
Publicado: (2016)

Integrin α(V)β(3) can substitute for collagen‐binding β(1)‐integrins in vivo to maintain a homeostatic interstitial fluid pressure
por: Lidén, Åsa, et al.
Publicado: (2018)

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
por: Metz, Silke, et al.
Publicado: (2012)

Stromal integrin α11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors
por: Smeland, Hilde Ytre-Hauge, et al.
Publicado: (2019)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

BEAT(® )the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs
por: Moretti, Pierre, et al.
Publicado: (2013)

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
por: Hutchings, Martin, et al.
Publicado: (2021)

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
por: Yadav, Rajbharan, et al.
Publicado: (2022)

THER-11. PEPTIDE-MEDIATED PERMEABILIZATION OF THE BLOOD-BRAIN BARRIER IMPROVES DRUG DELIVERY TO BRAIN METASTASIS
por: Aasen, Synnøve Nymark, et al.
Publicado: (2019)

Homogeneous Bispecifics by Disulfide Bridging
por: Hull, Elizabeth A., et al.
Publicado: (2014)

Design and Production of Bispecific Antibodies
por: Wang, Qiong, et al.
Publicado: (2019)

Bispecific Antibodies for Diagnostic Applications
por: Parashar, Archana, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vqcsg6umhvl7shn6l8g8ik3vmc